List of Reclast drug patents

Reclast is owned by Novartis.

Reclast contains Zoledronic Acid.

Reclast has a total of 3 drug patents out of which 0 drug patents have expired.

Reclast was authorised for market use on 16 April, 2007.

Reclast is available in injectable;intravenous dosage forms.

Reclast can be used as treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis.

The generics of Reclast are possible to be released after 05 August, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8052987 NOVARTIS Method of administering bisphosphonates
Oct, 2023

(8 months from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates
Feb, 2028

(5 years from now)

US7932241

(Pediatric)

NOVARTIS Pharmaceutical products comprising bisphosphonates
Aug, 2028

(5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 16 April, 2007

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of RECLAST before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in